Available treatment options for Parkinson's disease (PD) are primarily aimed at pharmacological and/or neurosurgical management of motor symptoms. However, many patients also experience chronic non-motor symptoms (NMS), including significant cognitive and mood changes. Currently, there is a gap in the neuropsychological literature regarding the efficacy of nonpharmacological treatment options for cognitive and mood changes in PD.
Objective:
We sought to evaluate the efficacy and patient satisfaction of a pilot nonpharmacological intervention for alleviating NMS in patients with PD.
Methods:
Twenty-three independently functioning nondemented patients with PD participated in a 5-week Parkinson’s Disease Enrichment Program. Each 4-hour weekly session included content which addressed the following components: education, exercise, recreation, and socialization/support. Participants received a pre-assessment, including cognitive tests and questionnaires for depression and quality of life. After the completion of the program, participants completed post-assessment batteries to measure changes in neurocognitive and psychiatric status, as well as patient satisfaction regarding the program.
Results:
Neuropsychological data from pre- and post-assessments revealed significant improvements in measures of executive functioning, memory, and depressive symptoms. No significant changes were observed on the remaining mood or cognitive measures. One hundred percent of participants reported enjoyment from socialization with other participants with PD and satisfaction with the program overall.
Conclusions:
Positive preliminary results suggest that further expansion of this nonpharmacological pilot program for treatment of NMS may be beneficial for patients with PD. Future studies will investigate a larger cohort of participants with PD and cross-validate findings in demographically diverse samples.
ArmentoMEStanleyMAMarshL. Cognitive behavioral therapy for depression and anxiety in Parkinson’s disease: a clinical review. J Parkinsons Dis. 2012;2(2):135–151.
2.
de LauLMBretelerMM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535.
3.
KowalSLDallTMChakrabartiRStormMVJainA. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–318.
4.
ChaudhuriKRHealyDGSchapiraAH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
5.
Martinez-MartinPRodriguez-BlazquezCKurtisMMChaudhuriKR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.
6.
SchragAHovrisAMorleyDQuinnNJahanshahiM. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12(1):35–41.
7.
AarslandDBronnickKWilliams-GrayC. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069.
8.
JanvinCCAarslandDLarsenJP. Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. 2005;18(3):149–154.
9.
LehSEPetridesMStrafellaAP. The neural circuitry of executive functions in healthy subjects and Parkinson’s disease. Neuropsychopharmacology. 2010;35(1):70–85.
10.
AarslandDPerryRBrownALarsenJPBallardC. Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol. 2005;58(5):773–776.
11.
EmreMAarslandDBrownR. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007; 22: 1689–707.
12.
ChaudhuriKRSchapiraAH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009; 8: 464–74.
13.
LewisSJDoveARobbinsTWBarkerRAOwenAM. Cognitive impairments in early Parkinson’s disease are accompanied by reductions in activity in frontostriatal neural circuitry. Journal Neurosci. 2003;23(15):6351–6356.
14.
MarshLBiglanKGerstenhaberMWilliamsJR. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord. 2009;24(2):277–82.
15.
EmreM. Dementia associated with Parkinson’s disease. Lancet Neurol. 2003;2(4):229–237.
16.
DuboisBPillonB. Cognitive deficits in Parkinson’s disease. J Neurol. 1996;244(1):2–8.
17.
LeesAJSmithE. Cognitive deficits in the early stages of Parkinson’s disease. Brain. 1983;106(pt 2):257–270.
LevinBETomerRReyGJ. Cognitive impairments in Parkinson’s disease. Neurol Clin. 1992;10(2):471–485.
20.
MarshL.Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13(12):409.
21.
PapapetropoulosSEllulJArgyriouAAChroniELekkaNP. The effect of depression on motor function and disease severity of Parkinson’s disease. Clin Neurol Neurosurg. 2006;108(5):465–469.
22.
ReijndersJSEhrtUWeberWEAarslandDLeentjensAF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–189.
23.
WeintraubDMobergPJDudaJEKatzIRSternMB. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16(3):178–183.
24.
JankovicJ. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
25.
ShulmanLMTabackRLRabinsteinAAWeinerWJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8(3):193–197.
26.
CalleoJSAmspokerABSarwarAI. A pilot study of a cognitive–behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol. 2015;28(3):210–217.
27.
RascolOBrooksDJMelamedE. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–954.
28.
ThomasAIaconoDLucianoALArmellinoKDi IorioAOnofrjM. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–143.
29.
OndoWGTintnerRVoungKDLaiDRingholzG. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–963.
30.
Saint-CyrJATaylorAELangAE. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology. 1993;43(12 suppl 6):S47–S52.
31.
BaronePPoeweWAlbrechtS. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.
32.
DobkinRDMenzaMBienfaitKL. CBT for the treatment of depression in Parkinson’s disease: a promising non-pharmacological approach. Expert Rev Neurother. 2008;8(1):27–35.
33.
DobkinRDAllenLAMenzaM. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord. 2007;22(7):946–952.
34.
DobkinRDMenzaMAllenLA. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–1074.
35.
FarabaughALocascioJJYapL. Cognitive–behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics. 2010;51(2):124–129.
36.
NaismithSLMowszowskiLDiamondKLewisSJ. Improving memory in Parkinson’s disease: a healthy brain ageing cognitive training program. Mov Disord. 2013;28(8):1097–1103.
37.
ParísAPSaletaHGde la Cruz Crespo MaraverM. Blind randomized controlled study of the efficacy of cognitive training in Parkinson’s disease. Mov Disord. 2011;26(7):1251–1258.
38.
SammerGReuterIHullmannKKapsMVaitlD. Training of executive functions in Parkinson’s disease. J Neurol Sci. 2006;248(1-2):115–119.
NasreddineZSPhillipsNABédirianV. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
41.
BeckATSteerRABrownGK. Beck Depression Inventory—Second Edition Manual. San Antonio, TX: The Psychological Corporation; 1996.
42.
BrandtJ.The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5(5):125–142.
43.
WechslerD. WAIS-III, Wechsler Adult Intelligence Scale: Administration and Scoring Manual. San Antonio, TX: Psychological Corporation; 1997.
44.
ReitanRWolfsonD. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1985.
45.
StroopJR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643.
46.
DelisDCKaplanEKramerJ. Delis Kaplan Executive Function System. San Antonio, TX: The Psychological Corporation; 2001.
47.
WilsonBAAldermanNBurgessPWEmslieHEEvansJJ. Behavioral Assessment of the Dysexecutive Syndrome. Suffolk, England: Thames Valley Test Company; 1996.
48.
JenkinsonCFitzpatrickRPetoVGreenhallRHymanN. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health. 1997;12(6510):805–814.
49.
CohenLS. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
50.
MorrisSBDeShonRP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7(1):105–125.
51.
FosterERGoldenLDuncanRPEarhartGM. Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson’s disease. Arch Phys Med Rehabil. 2013;94(2):240–249.
52.
McKeeKEHackneyME. The effects of adapted tango on spatial cognition and disease severity in Parkinson’s disease. J Motor Behav. 2013;45(6):519–529.
53.
PacchettiCManciniFAglieriRFundaròCMartignoniENappiG. Active music therapy in Parkinson’s disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000;62(3):386–393.
ChiesaACalatiRSerrettiA. Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev. 2011;31:449–464.
56.
ChurchillJDGalvezRColcombeSSwainRAKramerAFGreenoughWT. Exercise, experience and the aging brain. Neurobiol Aging. 2002;23(5):941–955.
57.
RogersRLMeyerJSMortelKF. After reaching retirement age physical activity sustains cerebral perfusion and cognition. J Am Geriatr Soc. 1990;38(2):123–128.
58.
TaddeiSGalettaFVirdisA. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation. 2000;101(25):2896–2901.
59.
CotmanCWBerchtoldNC. Exercise: a behavioural intervention to enhance brain health and plasticity. Trends Neurosci. 2002;25(6):295–301.
60.
Gómez-PinillaFSoVKesslakJP. Spatial learning and physical activity contribute to the induction of fibroblast growth factor: neural substrates for increased cognition associated with exercise. Neuroscience. 1998;85(1):53–61.
61.
NeeperSAGomez-PadillaFChoiJCotmanC. Exercise and brain neurotrophins. Nature. 1995;373(6):109.
62.
MathurSDeWitteSRobledoIIsaacsTStamfordJ. Rising to the challenges of clinical trial improvement in Parkinson’s disease. J Parkinsons Dis. 2015;5(2):263–268.
63.
WillisAWEvanoffBALianMCriswellSRRacetteBA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143–151.
